Inici › Leucèmia mieloide aguda › Kentucky
Assaigs clínics de Leucèmia mieloide aguda a Kentucky
14 estudis de Leucèmia mieloide aguda busquen participants en centres de Kentucky.
Ciutats de Kentucky
Text oficial de l'estudi (anglès)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Elizabeth Healthcare Edgewood, Edgewood
- i 5 més
ReclutantEstudi observacionalVoluntaris sans benvinguts
Edats de 40 a 75 · Tots els sexes · Actualitzat el 2 d’oct. 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
ReclutantFase 2
Edats de 18 a 59 · Tots els sexes · Actualitzat el 28 de set. 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- University of Kentucky Markey Cancer Center, Lexington
- UofL Health Brown Cancer Center, Louisville
- Norton Cancer Institute, Louisville
ReclutantFase 3
Edats de 18 anys en endavant · Tots els sexes · Actualitzat el 25 de set. 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
ReclutantFase 2
Edats de 18 anys en endavant · Tots els sexes · Actualitzat el 25 de set. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
ReclutantFase 2
Edats de 18 anys en endavant · Tots els sexes · Actualitzat el 22 de set. 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
ReclutantFase 2
Edats de 18 anys en endavant · Tots els sexes · Actualitzat el 22 de set. 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
ReclutantFase 2
Edats de 18 a 59 · Tots els sexes · Actualitzat el 22 de set. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
ReclutantFase 3
6 Months – 21 Years · Tots els sexes · Actualitzat el 17 de set. 2026 · NCT04293562Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
ReclutantFase 3
Edats de 1 a 25 · Tots els sexes · Actualitzat el 4 de set. 2026 · NCT07022678The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
ReclutantFase 1/2
Fins a 22 anys · Tots els sexes · Actualitzat el 25 d’ag. 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Norton Children's Hospital, Louisville
ReclutantFase 3
29 Days – 21 Years · Tots els sexes · Actualitzat el 24 d’ag. 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Kentucky, Lexington
ReclutantFase 3
Edats de 18 anys en endavant · Tots els sexes · Actualitzat el 20 d’ag. 2026 · NCT07007312A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Louisville Hospital - James Brown Cancer Center, Louisville
ReclutantEstudi observacional
Totes les edats · Tots els sexes · Actualitzat el 6 de jul. 2026 · NCT01351545A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Kentucky Markey Cancer Center, Louisville
- Norton Cancer Institute - St. Matthews, Louisville
ReclutantFase 1
Edats de 18 anys en endavant · Tots els sexes · Actualitzat el 13 de març 2026 · NCT05735184De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.